Table 1.
A summary of the various laboratories and institutes involved in plasma medicine research, predominantly the application of plasma plume technologies for topical (e.g., dermal) applications, and/or to perform in vitro cell assay experiments
| University / Institute | Application | Ref. |
|---|---|---|
| Ajou University | Cancer (in vitro) | 24–30 |
| Changchun University of Science and Technology | Cancer (in vitro) | 31 |
| Clemson University | Melanoma (in vitro) | 32 |
| Conway Institute of Biomolecular and Biomedical Research | Cancer (in vitro) | 33 |
| CSIRO | Cancer (in vitro) | 34,35 |
| Drexel University | Dermal applications; disinfection; melanoma (in vivo); cancer (in vitro) | 36–48 |
| Dong-A University | Cancer (in vitro) | 49–52 |
| Eindhoven University of Technology | Disinfection, cancer (in vitro) | %53 |
| George Washington University | Fibroblast modification; wound healing; cancer (in vitro); electrosurgery | %54–%67 |
| Heinrich-Heine University | Skin infection, wound healing | %68 |
| Kanazawa University | Wound healing | %69 |
| Korea Advanced Institute of Science and Technology | Cancer (in vitro) | %70 |
| Kwangwoon University Plasma Bioscience Research Center | Cancer (in vitro) | %71–%73 |
| Leibniz Institute for Plasma Science and Technology | Dermal applications; cancer (in vitro) | %74–%88 |
| Max Planck Institute | Dermal applications; cancer (in vitro) | %89–%91 |
| McGill University | Cancer (in vitro) | %92,%93 |
| Nagoya University | Cancer (in vitro); anti-fungal; macular degeneration | %94–%104 |
| National Institute for Laser, Plasma, and Radiation Physics | Cancer (in vitro) | %105 |
| Old Dominion University | Fungal decontamination, cancer (in vitro) | %106,%107 |
| Plasma Engineering Research Lab, Texas A&M | Surface decontamination, antibiotic-resistant bacteria, wound treatment, cancer (in vitro) | %108–%117 |
| Pohang University | Melanoma | %118,%119 |
| Pusan National University | Melanoma | %120 |
| Queen's University Belfast Centre for Plasma Physics | Nosocomial infection prevention, biofilm eradication, cancer (in vitro) | %121–%128 |
| Shahid Beheshti University | Melanoma | %129 |
| Umversite' d'Orleans | Subcutaneous tumor treatement (murine model) | %130–%134 |
| University of Buffalo | Melanoma | %135,%136 |
| University of Campinas | Fibroblast modification | %137 |
| University of Iasi | Dermal applications | %138 |
| University of Notre Dame | Cancer (in vitro) | %139 |
| York Plasma Institute, University of York | Cancer (in vitro) | %140 |